This study investigated the beneficial effects of co-administering anti-diabetes medication metformin (Glucophage) and doxorubicin (Adriamycin)-cyclophosphamide (Cytoxan) with paclitaxel (Taxol) (AC-T) chemotherapy in non-diabetic patients with breast cancer (BC). The data showed that metformin reduced the occurrence and severity of toxicities associated with AC-T chemotherapy in patients with BC.

The study evaluated the effectiveness of compression bandages applied with different pressures on the skin and subcutaneous tissue in patients with breast cancer-related lymphedema (BCRL). The study concluded that high-pressure compression bandage was more effective in reducing skin and subcutaneous tissue thickness and inflammation in patients with BCRL. 

The study evaluated the follow-up results of abemaciclib (Verzenio) plus endocrine (hormonal) therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive, and high-risk early breast cancer (BC). The data found that with a 4-year follow-up, adjuvant abemaciclib continued to show improvement in reducing the risk of recurrence in these patients.

The study evaluated the effectiveness of aquatic therapeutic exercise in breast cancer survivors for improving symptoms and quality of life. The study found that aquatic therapeutic exercise effectively improved fatigue, pain, and quality of life in these patients.

This study evaluated the effectiveness and safety of oral paclitaxel (Taxol) plus encequidar (HM 30181) versus intravenous (IV) paclitaxel in patients with metastatic breast cancer (BC). This study concluded that oral paclitaxel plus encequidar was more effective than IV paclitaxel with manageable side effects in these patients.

This study evaluated the effects of aquatic physical therapy on improvement in fatigue symptoms and quality of life (QoL) in patients with breast cancer (BC). The data showed that aquatic physical therapy reduced fatigue symptoms and improved the QoL in women with BC.

This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these patients with manageable side effects.

This study evaluated the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer. The data showed that most patients with breast and gynecological cancer developed antibodies after the second dose of the vaccine. However, the authors suggested that for non-responders or weak responders, additional immunization booster seems to be required, along with proactive planning in the vaccination schedule, with vaccine administration spaced out over time with respect to chemotherapy.

The study evaluated the effectiveness and safety of Q-122, a new non-hormonal oral treatment for menopausal symptoms in women with breast cancer taking hormonal therapy. The study found that Q-122 is effective and safe in treating menopausal symptoms in these patients.

The study evaluated the effectiveness of three exercise programs in improving quality of life (QOL), pain, and lymphedema among breast cancer (BC) survivors. The study found that joint mobility exercise (JME) combined with progressive resistance exercise (PRE) showed promising results in improving QOL and lymphedema after BC surgery.